Any current/future new fundraising through debt or equity?

The company has completed the planned capex, with only a marginal increase of around INR 5 crore related to CAPA implementation. Borrowings for the balance capex and CAPA have already been tied up; no further increase in borrowings or capex is planned. Term loan repayment has already started, and no new debt is anticipated. Working capital levels and debt gearing are stable, with no further debt increase expected. There is no mention of any new equity fundraising plans in the provided text.

Any current/future capex/capital investment/strategic investment?

The previously planned capex has been mostly completed. There is a marginal additional capex of around INR 5 crore related to CAPA implementation. Another INR 5 to 7 crore is planned for completion of balance capex, with borrowings already tied up. No significant further increase in borrowing or capex is expected beyond these amounts. The CAPA-related capex is approved by the Board. No mention of strategic investments beyond remedial and capex activities shared.

Future growth expectations in sales/revenue/volumes?

The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall. NIP (New Innovative Products) and OTF (Orally Thin Films) sales are anticipated to return to approx. INR 15–16 crores run rate in Q3 and Q4 FY '26. India and export order books remain strong, supporting revenue recovery in H2 FY '26 and beyond. New Marketing Authorizations (MAs) recently received—especially in ROW markets—are expected to commercialize within 3 to 6 months, driving growth. EU-GMP compliance and remediation expected by Q4 FY '26 will enable resum

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1. Improvement in EBITDA expected in H2 FY '26 as 60% of sales ramp-up occurs, with gross contribution improving from 49.3% to 51%. EBITDA for FY '25 was INR44 crores; H2 FY '26 target around INR30 crores, indicating a recovery trajectory. FY '27 outlook is optimistic with expectations of 20%-25% revenue growth and EBITDA margins of around 14%-15%, contingent on successful EU-GMP certification and remediation. Margin improvement driven by product mix normalization, operational ef

Current/ Expected Orderbook/ Pending Orders?

The company has a robust order book with orders already in hand, providing confidence for achieving year-end targets similar to the previous year. For innovative products like NIP and OTF, there was a shortfall in H1 due to audit-related prudence delaying order execution, but orders are moderating and expected to compensate in H2. Orders that were delayed in H1 for some customers are expected to come in H2, aiming to reach prior run rates of around INR 15-16 crores per quarter for NIP and OTF products. The business plan anticipates roughly 60% of annual business in H2, based on existing

IN US

Sale is live|00:00:00left today

Zim Laboratories LtdQ3 FY25Pharmaceuticals & Biotechnology

Zim Laboratories Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹126P/E: 75.2Market Cap: ₹526 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall.
→NIP (New Innovative Products) and OTF (Orally Thin Films) sales are anticipated to return to approx. INR 15–16 crores run rate in Q3 and Q4 FY '26.
→India and export order books remain strong, supporting revenue recovery in H2 FY '26 and beyond.
→New Marketing Authorizations (MAs) recently received—especially in ROW markets—are expected to commercialize within 3 to 6 months, driving growth.
→EU-GMP compliance and remediation expected by Q4 FY '26 will enable resumption of EU market sales starting Q1 or Q2 FY '27.
→Management targets 20–25% revenue growth and improved margins (14–15% EBITDA) in FY '27, assuming timely EU sales restart.
→Nutra segment demand expected to stabilize in Q3/Q4 FY '26 with institutional orders recovering.
→Working capital and inventory levels will rise proportionate to turnover growth.

Margin guidance

Category 3

→The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1.
→Improvement in EBITDA expected in H2 FY '26 as 60% of sales ramp-up occurs, with gross contribution improving from 49.3% to 51%.
→EBITDA for FY '25 was INR44 crores; H2 FY '26 target around INR30 crores, indicating a recovery trajectory.
→FY '27 outlook is optimistic with expectations of 20%-25% revenue growth and EBITDA margins of around 14%-15%, contingent on successful EU-GMP certification and remediation.
→Margin improvement driven by product mix normalization, operational efficiencies, and resumption of innovative product sales starting from Q1 or Q2 FY '27.
→Capex largely completed with minor additional spends (~INR5 crores) for CAPA implementation, no significant borrowing increase expected.
→Working capital to increase proportionately with turnover; gearing ratios expected to remain stable.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company has completed the planned capex, with only a marginal increase of around INR 5 crore related to CAPA implementation.
→Borrowings for the balance capex and CAPA have already been tied up; no further increase in borrowings or capex is planned.
→Term loan repayment has already started, and no new debt is anticipated.
→Working capital levels and debt gearing are stable, with no further debt increase expected.
→There is no mention of any new equity fundraising plans in the provided text.

Order book

Yes

→The company has a robust order book with orders already in hand, providing confidence for achieving year-end targets similar to the previous year.
→For innovative products like NIP and OTF, there was a shortfall in H1 due to audit-related prudence delaying order execution, but orders are moderating and expected to compensate in H2.
→Orders that were delayed in H1 for some customers are expected to come in H2, aiming to reach prior run rates of around INR 15-16 crores per quarter for NIP and OTF products.
→The business plan anticipates roughly 60% of annual business in H2, based on existing orders and expected government orders.
→The company has built inventory and secured orders for the second half to compensate for the shortfall in H1.
→Continued growth visibility exists due to marketing authorizations received, and new product commercialization timelines of 3-6 months post-approval.

Capex plans

Yes

→The previously planned capex has been mostly completed.
→There is a marginal additional capex of around INR 5 crore related to CAPA implementation.
→Another INR 5 to 7 crore is planned for completion of balance capex, with borrowings already tied up.
→No significant further increase in borrowing or capex is expected beyond these amounts.
→The CAPA-related capex is approved by the Board.
→No mention of strategic investments beyond remedial and capex activities shared.

How does Zim Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zim Laboratories Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zim Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio